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Nitric oxide synthase: An endogenous source of elevated nitrite in
infected urine. To further define the endogenous sources of urine nitrite
in urinary tract infections, we measured urinary nitrite levels by the
Griess method and assayed urinary nitric oxide (NO) synthase activity
by the conversion of '4C-arginine to '4C-citrulline. Endogenous produc-
tion of '4C-citrulline was confirmed by thin layer chromatography.
Exogenous L-arginine increased nitrite production in whole infected
urine, but not in bacteria isolated from infected urine. Urinary tract
infections significantly increased NO synthase activity in soluble urine
fractions, although soluble activity was less than 10% of particulate
activity. Urine particulate fractions from women with non-infected
urine had greater NO synthase activity than particulate fractions from
men with non-infected urine, 11 2 and 0.2 0.1 picomol/minlmg
protein, respectively. Urinary tract infections increased NO synthase
activity in urine particulate fractions from women and men, 99 20and
48 9 picomollmin/mg protein, respectively. The conversion of '4C-
arginine to '4C-citrulline required NADPH, was calcium independent,
and was inhibited to a greater extent by L-canavanine than by N°-
monomethyl-L-arginine or N°-nitro-L-arginine. Human infected urine
contains an isoform of NO synthase which is an endogenous source of
urine nitrite.
A direct relationship exists between urine nitrite levels and
urinary tract infection [1]. The nitrite test, first described by
Griess [21, has been used as a simple and rapid method for
detecting bacteriuria since many bacterial species convert en-
dogenous nitrate to nitrite. Nitric oxide (NO) is a potential
endogenous source of infected urine nitrite detected by the
Griess reagent. NO synthase, which has been localized in
several mammalian cells including macrophages, converts
L-arginine to nitric oxide and citrulline in a NADPH-dependent
reaction [3—5]. Nitrite is an oxidation product of nitric oxide. In
rodents, the induced form of NO synthase has been defined as
a source of reactive nitrogen intermediates in anti-tumor and
anti-microbial activities; however, defining human macrophage
NO synthase activity has been difficult [6—8]. Human macro-
phages derived from cultured peripheral blood monocytes have
not consistently produced detectable nitrite levels in response
to stimulus [7]. Therefore, to elucidate the mechanisms of
urinary nitrite formation detected by the Griess reaction and to
characterize human inflammatory nitric oxide synthase activity,
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we measured both the nitrite concentration and nitric oxide
synthase activity in human infected and non-infected urine.
Methods
Urine sample isolation
Urine specimens from symptomatic emergency room and
urology clinic patients (N = 18) were submitted to the Clinical
Microbiology Laboratory at the Yale-New Haven Hospital
after routine urinalysis. The majority (87%) were clean-catch
midstream specimens; the remainder (13%) were obtained by
sterile catheterization. Patients' symptoms included dysuria,
frequency, urgency, lower abdominal and flank pain, and fever.
For the purpose of this study, significant bacteriuria was
defined as a colony count of greater than io CFU/ml of a
clearly predominating microorganism. Escherichia coli (E. coli)
grew in sixteen samples, Serratia in one sample, and Kiebsiella
in one sample. Ten control urine specimens were obtained from
asymptomatic men and women. Control urine samples were
negative by reagent strip urinalysis and had less than five white
blood cells per milliliter by microscopic exam. All control urine
specimens were clean-catch midstream specimens.
Filtration of urine
To isolate bacteria from inflammatory cells, urine (3 ml) was
filtered through a sterile, non-pyrogenic nylon filter with a 5.0
m pore size (Micron Separations Inc., Westboro, Massachu-
setts, USA). Bacteria were, thus, isolated in the filtrate as
confirmed by microscopy. Leukocytes did not pass through the
filter. Because bacteria may contaminate the leukocyte frac-
tion, the filtrates (bacteria-enriched samples) were used in the
Griess-nitrite determinations.
Griess reaction
The nitrite concentration in whole urine and urine filtrate was
determined by the Griess reaction [2]. Nitrite reacts with 1%
sulfanilamide in 5% H3P04/0. 1% naphthalene-efhylenediamine
dihydrochloride forming a chromophore (pink to dark red color)
absorbing at 546 nm. The Griess reaction was performed
immediately after receiving urine samples and was repeated
after 37°C incubation of urine for four and eight hours. The
Griess reagent (500 l) was added to urine (100 /hl) and H20 (400
pi) or NaNO2 standards (0.1 to 4.0 jsg/500 .d H20) and the
samples and standards were incubated 15 minutes at room
temperature before reading the absorbance.
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Assay of nitric oxide synthase
Urine (stored on ice) was centrifuged at 1700 x g (10 mm,
0°C) to isolate the pellet [9]. The urine pellet was resuspended
in ice-cold phosphate buffered saline and centrifuged at 1700 x
g. The resultant pellet was resuspended in an ice-cold homog-
enization buffer (1 vol pellet/b vol buffer) which consisted of 20
mM Hepes (pH 7.2), 1.0 mrvi DTF, leupeptin (0.2 mg/lOO ml) and
1.0 mg/100 ml of soybean trypsin inhibitor, pepstatin, PMSF,
antipain, and chymostatin. The resuspended pellet was homog-
enized (10 seconds, at 70% power) using a Polytron PT 10/35
homogenizer equipped with a PTA 7 K! generator (Brinkmann,
Westbury, New York, USA) and the homogenate was centri-
fuged at 27,000 x g for 45 minutes at 4°C. The resultant
particulate fraction was resuspended in 1.5 ml of homogeniza-
tion buffer containing 1.0 M KCI after isolation of supernatant.
The particulate fraction was centrifuged at 27,000 X g for 45
minutes (0°C), resuspended in homogenization buffer, centri-
fliged 27,000 x g for 45 mm (0°C), resuspended in homogeni-
zation buffer, centrifuged 27,000 x g for 45 minutes and
resuspended again in homogenization buffer so that the final
enzyme hydrolyzed less than 30% of '4C-L-arginine. The su-
pernatant was passed over a 1.0 ml AG 50W-X8 column to
remove endogenous arginine before assay. Samples were stored
at —80°C until assay without loss of activity.
Nitric oxide synthase activity was measured as the formation
of '4C-citrulline from '4C-arginine. The particulate or soluble
enzyme (150 d) or buffer control (150 p1 of homogenization
buffer) and 50 p1 of homogenization buffer containing (final
concentration): 3 sM '4C-L-arginine (0.2 .tCi), 2.0 mM
NADPH, and 1.0 mri CaC12 were incubated at 37°C for 45
minutes. The reaction was linear for at least 45 minutes. NO
synthase inhibitors, when used, were added prior to incubation.
The assay was terminated with 1.0 ml of 20 ifiM Hepes (pH 5.5)
containing 2.0 mri EDTA. The sample was applied to a 1.0 ml
column of AG 50W-X8 (Na form) and eluted with 1.0 ml of
Hepes (pH 5.5). The column effluent was measured in a liquid
scintillation counter. The buffer control cpm values were sub-
tracted from all other sample values. Protein concentrations
were measured by the Bio-Rad Protein Assay using bovine
gamma-globulin as a standard. Insoluble samples were hydro-
lyzed in NaOH prior to the protein assay. The average protein
in supernatant and particulate fractions was 0.23 0.03 mg/ml
and 0.24 0.05 mglml, respectively.
Determination of Km
The Km values were determined by computer-assisted curve
fitting to a predefined Michaelis-Menton equation. Four partic-
ulate urine samples were passed over a 1.0 ml column of AG
SOW-X8 (Nat form) to remove endogenous arginine and then,
arginine (3 /sM to 200 M) was added and the 14C-citrulline
production at these concentrations fitted on the curve.
Thin layer chromatography
After completing the enzyme assay and column separation,
thin layer chromatography [10] was performed on control buffer
samples and on samples containing particulate fractions from
non-infected urine, infected urine, urine filtrate, or E. coli
(isolated by the Yale-New Haven microbiology laboratory from
urine cultures grown on blood and MacConkey agar plates).
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Fig. 1. Effect of infection and incubation time on urine nitrite produc-
tion as measured by the Griess method. Each data point is the mean
SEM of the urine nitrite concentrations from at least five different
donors. Asterisk represents a 95% significance level between control
(A) and infected (0) urine.
Post-column-separation samples (50 to 100 d) and 10 p1 of
L-arginine (1.0 mg/mI), ornithine (1.0 mg/ml) and citrulline (1.0
mg/ml) were applied to silica-gel plates (Sigma, #T-6395) and
developed with a chloroform-methanol-ammonium hydroxide-
water solvent system (0.5 : 4.5 : 2.0: 1.0).
Materials used
NGmonomethylLarginmne, NGnitroLarginine, L-canava-
nine, NADPH, and all protease inhibitors were obtained from
Sigma Chemical Company (St. Louis, Missouri, USA).
L-[14C(U)]-arginine (340 mCi/mmol) was obtained from Du-
Pont/NEN (Wilmington, Delaware, USA). AG 50W-X8 (Nat
form) was obtained from Bio-Rad (Richmond, California,
USA).
Data and statistical analyses
Results were expressed as mean SEM. Means were com-
pared using analysis of variance (ANOVA) followed by the
Scheffe F-test. Multi-comparison significance level was 95%.
Results
Urine and urine-filtrate nitrite levels in the presence of
arginine or nitrate
Nitrite levels in control and infected urine samples were
measured by the Griess method immediately after receiving
urine samples and after urine incubation (37°C) for four and
eight hours. Samples were also exposed to 1.0 mri L-arginine or
1.0 mM NaNO3 (nitrate) and incubated for four hours. Control
urine samples, after addition of the Griess reagent, did not
change color. Control urine nitrite levels, measured by spectro-
photometry, were always less than infected urine levels and did
not change with time or the addition of L-arginine or nitrate.
Figure 1 shows the significant elevation of nitrite with time in
infected urine samples. The nitrite concentration measured in
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Fig. 2. Percent change in nitrite concentration after addition of argi-
nine () or nitrate (U) to infected urine samples before and after
filtration through a 5 iun pore filter. The nitrite concentration was
measured in infected urine (N = II) and urine filtrate (N = 3) after
incubation (37°C, 4 hr) and compared to incubated infected urine
exposed to 1.0 mai arginine or nitrate. The percent increase in nitrite
concentration is reported as the mean SEM. Asterisk represents P <
0.01.
values obtained from infected urine exposed to 1.0 mM L-argi-
nine or 1.0 mM nitrate and incubated for four hours at 3TC.
Infected urine nitrite production increased 102 27% with the
addition of exogenous arginine and 124 35% with the addition
of nitrate (N = 11). In urine filtrate samples, exogenous arginine
did not increase nitrite production; however, nitrate did (33
11%). All percent increases were significant (P < 0.01, N =3;
Fig. 2).
NO synihase activity in urine pellet isolated from men and
women with and without genitourinary tract infection
As shown in Figure 3A, >4C-product activity (pmol arginine
metabolized/mm/mg protein) was significantly elevated in male
and in female infected urine pellets (49 9 and 121 25,
respectively). Particulate 14C-product activity in women with-
out urinary tract infection was 18 times greater than in men
without infection (14 3 and 0.8 0.2, respectively). 14C-
product activity in the supernatant, while much lower than the
particulate effluent activity increased four- and 11-fold in men
and women with infection when compared to uninfected con-
trols (Fig. 3B). The Km for enzyme activity, using 3.0 to 200 tM
arginine substrate, in urine particulate fractions was 18 5 M
L-arginine (N = 4).
Thin layer chromatography of control urine (without
infection), infected urine, urine filtrate, and E, coli
particulate fractions
When the particulate fraction of urine filtrate was assayed,
significant radioactivity (1900 CPMIIOO s1 effluent) was found in
the column effluent. This activity was inhibited by heating the
enzyme but was not inhibited by NO synthase inhibitors. Thus,
thin layer chromatography was used to determine what percent-
age of the measured radioactivity migrated with citrulline.
Fig. 3. A and B. DUferences in urine particulate and soluble '4C-
product activity between men and women with urinary tract infections
(B) and without urinary tract infections (U, control). Each value,
expressed as pmol '4C-product/min/mg protein, is based on assay
determinations from at least 5 different patients. Significance between
any of the four data points for particulate '4C-effluent activity is greater
than 95%. Significance between control and infected soluble '4C-








Buffer Control 458 37 169
E. coli 3366 13 438
Filtrate (infected urine) 1900 5 95
Control male urine 330 28 92
Control female urine 7950 75 5963
Infected male urine 8690 97 8429
Infected female urine 16460 82 13497
After completing the enzyme assay and column separation, TLC was
performed on the above named effluent samples. "Buffer control"
contains the Hepes assay solution but does not contain bacteria or
urine. The effluent radioactivity was measured prior to silica-gel-plate
application (cpm/100 1u1 effluent). The area on the plate corresponding to
each sample's citrulline production (R = 0.9) was isolated, counted,
and reported as a percentage of effluent radioactivity.
Citrulline was clearly separated from ornithine and arginine by
TLC; the Rf values for arginine, ornithine, and citrulline were
0.52, 0.77, and 0.92, respectively [10]. NO synthase activity
was measured in samples containing only homogenization
buffer and in the particulate fractions from control urine,
infected urine, infected urine filtrate, or E. coil. As shown in
Table 1, there was no evidence of NO synthase activity in urine
filtrate samples. Radioactivity that migrated like citrulline was a
smaller percentage of the total radioactivity in E. coil, urine
ifitrate, and male control urine particulate fractions, than in the
sample containing only the Hepes buffer solution. TLC of
particulate fractions from infected urine showed that 82 to 97%
of the radioactivity migrated with citrulline. The particulate NO
synthase activity was corrected by multiplying '4C-product
activity by the percentage of '4C-citrulline formation measured
by TLC (Table 1). In male and in female infected urine pellets,
the corrected NO synthase activity is 48 9 pmollmin/mg and













































activity in noninfected urine from men and women is 0.2 0.1
and 11 2, respectively.
Differential inhibition of NO synthase by L-canavanine,
NGmonomethylLarginine (NMA), and NGnitroLarginine
(NNA)
NO synthase activity was measured in the presence of
L-canavanine, NMA, or NNA in infected and control urine
particulate fractions. As shown in Figure 4, L-canavanine,
NMA, and NNA (100 LM each) inhibited NO synthase activity
39±3%(N= 16),30±4%(N=5),and5±2%(N8),
respectively. The differential inhibition of NO synthase activity
was significant to 95% by the Scheffe F-test. Figure 5 illustrates
that L-canavanine (10, 100, and 1000 LM) inhibited enzyme
activity in a dose dependent manner [11 1.9% (N = 5), 39
3.3% (N = 8), and 68 4.2% (N = 14), respectively].
NO synthase activity in infected urine depended upon
NADPH but not calcium
NO synthase activity in particulate fractions did not decrease
significantly when assayed in the presence of 5.0 mM EGTA
without exogenous CaCI2. The average NO synthase activity
measurement for male and female infected urine samples in the
presence of CaCl2 (1.0 mM) was 81 14 pmol arginine metab-
olized!min/mg protein and NO synthase activity in infected
urine samples without calcium ion was 75 19 pmol arginine
metabolized/mm/mg protein (P =0.84). Similarly, control urine
particulate activity from both women and men did not decrease
in the absence of calcium (N = 8). Without NADPH, male and
female infected urine particulate enzyme activity decreased
94% from 81 14 to 4.5 0.8 pmol arginine metabolized!
mm/mg protein (P 0.01, N 8).
Discussion
These results show NO synthase activity in endogenous urine
cells. First, arginine increases nitrite production in whole








urine. Second, '4C citrulline, isolated by column chromatogra-
phy, is formed from '4C-L-arginine in both soluble and partic-
ulate urine fractions. Thin layer chromatography shows that
between 75% and 97% of the radioactivity in female control,
male infected urine, and female infected urine effluents migrate
with citrulline. In contrast, only 5 to 13% of the radioactivity in
bacterial effluent migrates with citrulline. Third, 14C-arginine
metabolism (NO synthase activity) is reduced 94% in the
absence of NADPH and 39% and 30% in the presence of
canavanine (100 M) and NMA (100 MM), respectively. Finally,
particulate and soluble NO synthase activities in infected urine
pellet are elevated.
Because many studies have confirmed the direct relationship
between urine nitrite and urinary tract infection, the Griess
reagent is used to screen urine for microorganisms. The false
positive rate is small (1 to 2%); however, when random urine
specimens are evaluated, the false negative rate can be greater
than 50% [11, 12]. The low sensitivity of the test has been
attributed to inadequate bacterial incubation, low urine pH,
urine contents such as urobilinogen, and the finding that some
bacteria do not reduce nitrate to nitrite [13].
Roy and Wilkerson [14] found fewer false negative results
with urine incubation, however, addition of KNO3 to urine
samples in their study did not increase significantly the sensi-
tivity of the Griess reaction. In the present experiment, both
time and the addition of NaNO3 increase nitrite levels in
infected urine. Furthermore, L-arginine increases nitrite in
whole infected urine but fails to increase nitrite in urine filtered
to remove endogenous inflammatory cells. Neither exogenous
nitrate nor arginine increase nitrite levels in non-infected urine.
These findings suggest that the Griess reagent may be more










Fig. 4. Percent inhibition of particulate NO synthase by NGnitroL
arginine (NNA; El), NGmonomethylLarginine (NMA; ), and
L-canavanine (•). Results are reported as percent inhibition SEM. 0
10 100 1000
Canavanine, pM
Fig. 5. Effect of increasing concentrations of L-canavanine on NO
synthase activity. L-canavanine (10, 100, 1000 M) inhibited infected
and control urine particulate NO synthase activity 11 2% (N = 5), 39
3% (N = 8), and 68 4% (N = 14), respectively.
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effective in detecting urinary tract infections if urine samples
are incubated for four hours in the presence of exogenous
arginme.
The regulation of NO synthase activity in infected urine is
similar to that of induced forms of activity that have been
described in rodent macrophages, inflammatory neutrophils,
and carcinoma cells [6]. In our experiment, despite the addition
of NO synthase inhibitors, some '4C-product is still generated.
Also, the TLC experiment reveals citrulline as 82 to 97% of
effluent radioactivity in infected urine, 75% of effluent radioac-
tivity in control female urine, and 28% of effluent radioactivity
in control male urine. NO synthase is not the only pathway by
which citrulline is generated. In murine macrophages and
bovine epithelial cells, arginine is metabolized to ornithine by
arginase. Ornithine, in turn, can be converted to citrulline by
transcarbamoylase [15, 16]. Only a small fraction of arginine is
utilized for new protein synthesis while large amounts of
L-arginine are consumed directly to L-ornithine and urea by
arginase and in activated cells, arginine follows the nitric oxide
synthase pathway [15—17]. Arginase is not inhibited by NO
synthase inhibitors and the activity of arginase is similar
whether or not macrophages are activated [17].
The NO synthase activity in infected urine is localized
primarily (>90%) in the KCI washed particulate fraction from
urine. Previously, inducible NOS has been described as solu-
ble, but recent reports describe NOS activity in RAW264.7
macrophages that is found in both particulate and soluble
fractions [18]. The enzyme activity in the particulate fraction
from infected urine pellet is inhibited to the greatest extent by
L-canavanine, less by NGmonomethylLarginine (NMA), and
not by N°-nitro-L-arginine (NNA). NO synthase activity in
infected urine pellet requires NADPH but is calcium indepen-
dent. Previous studies have shown that NNA preferentially
blocks the calcium/calmodulin-dependent NO synthase found
in brain, that NMA exhibits similar potencies against the
calcium/calmodulin-dependent and calciumlcalmodulin-inde-
pendent NO synthases, and that L-canavanine selectively in-
hibits the inducible form of enzyme activity that has been found
in macrophages [19—22]. The Km for the NO synthase activity in
the particulate fraction of human infected urine is 18 5 jLM
L-arginine. Lowenstein et al [23], after transfecting embryonic
kidney cells from humans with macrophage-NO synthase
cDNA from mice and measuring enzyme activity, report a Km
of 19 pM L-arginine. Other studies in mammalian tissues report
macrophage Km values between 2.8 and 32 M L-arginine and
an inflammatory-neutrophil Km of 22 M L-arginine [6].
Not only is nitric oxide synthase activity higher in infected
urine, but it is also higher in female control urine than in male
control urine. At this time, the significance of control urine NO
synthase activity can only be speculated. Like NO synthase
activity in infected urine, particulate NO synthase activity in
female control urine is calcium independent and inhibited to the
greatest extent by L-canavanine. In animals, several isoforms
of NO synthase have been identified and the inducible forms
have been calcium independent and selectively inhibited by
L-canavanine [6]. Maybe the NO synthase constitutive/induc-
ible dichotomy does not hold in humans. On the other hand, NO
synthase activity in female urine may be chronically induced
since about 4% of young women have bacteriuria and the
percentage of women with bactenuria rises with age [24].
Finally, the measured difference in NO synthase activity be-
tween male and female control urine maybe secondary to male
intrinsic NO synthase blocking agents not found in women.
Therefore, future studies using tools such as antibody and RNA
probes are needed to help distinguish the distinct forms of
human NO synthase and clarify the etiology of elevated or
decreased NO synthase activity in control urine.
Previous investigators have noted heterogeneity between
rodent and human macrophage nitrite production and expressed
concern over defining the role of nitric oxide synthase in human
inflammatory processes based on rodent studies [7]. In these
experiments, endogenous enzyme activity, from urine particu-
late fractions, that converts 14C-argimne to '4C-citrulline is
elevated in infected urine, is NADPH dependent, is calcium
independent, and is inhibited more by L-canavanine than by
NMA or NNA. These results describe nitric oxide synthase
activity in human inflammatory cells. Understanding the endo-
genous nitrite source may improve Griess-nitrite screening tests
for urinary tract infections and lead to distinguishing distinct
forms of human NO synthase.
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